The ground floor of the formulation development laboratory is focused on solid orals, the first floor on injections, and the second floor houses the analytical lab
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
RH Capital, a leading women's health venture capital fund, announced three new investments to improve health outcomes for women in the US.
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
Bempedoic acid helps lower cardiovascular risk in high or very high-risk atherosclerotic cardiovascular disease (ASCVD) patients as an add-on therapy to maximally tolerated statin and/or ezetimibe
Belmore, the brand name of Bempedoic acid, is a novel drug for the treatment of high LDL-cholesterol.
Leading pharma companies are achieving rapid, large-scale performance improvements using a multifaceted approach that realizes short-term gains & builds long-term capabilities at the same time
Bempedoic Acid administered as a 180-mg dose, is approved by the USFDA and European Union for the treatment of hypercholesterolemia
To lay a technological foundation for developing exosome-based medicines and cosmetic products for dermatitis treatment
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
Subscribe To Our Newsletter & Stay Updated
